CAPRICOR THERAPEUTICS

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy

28 Jun 2024 09:00:00 By Nasdaq GlobeNewswire

CORRECTION: Capricor Therapeutics

25 Jun 2024 10:30:57 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy

25 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway

11 Jun 2024 09:25:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

04 Jun 2024 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

13 May 2024 16:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

09 May 2024 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences

08 May 2024 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13

06 May 2024 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

24 Apr 2024 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Upcoming Investor Conferences

21 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

06 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

29 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy

27 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

22 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization

20 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

24 Jan 2024 09:15:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

11 Dec 2023 09:00:00 By Nasdaq GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

14 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14

07 Nov 2023 09:15:00 By Nasdaq GlobeNewswire